NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos is presenting four scientific posters, based on collaborations with Drs. Qihong Huang and Kiranmai Gumireddy of the Wistar Institute, Philadelphia PA, and Drs. Kenneth Tew, Danyelle Townsend and Yefim Manevich of the Medical University of South Carolina, Charleston, SC, at the ongoing American Association for Cancer Research (AACR) 2009 Annual Meeting in Denver, CO. These four posters present findings in animal and cellular model systems that add to the understanding of the pharmacological actions of NOV-002 and how these may relate to its clinical profile in oncology patients. An abstract of each poster presentation has been published in the conference proceedings. NOV-002 is in a pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, which is expected to conclude in late 2009. NOV-002 has also demonstrated positive results in Phase 2 trials for other cancer indications.
